Westlake BioPartners Fund I, L.P. - 07 Feb 2024 Form 3 Insider Report for Kyverna Therapeutics, Inc. (KYTX)

Role
10%+ Owner
Signature
By: /s/ Jennifer L. Kercher, as Attorney-in-Fact
Issuer symbol
KYTX
Transactions as of
07 Feb 2024
Net transactions value
$0
Form type
3
Filing time
07 Feb 2024, 21:51:12 UTC
Next filing
14 Feb 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding KYTX Series A-1 Redeemable Convertible Preferred Stock 07 Feb 2024 Common Stock 967,188 See Footnote F1, F2
holding KYTX Series A-2 Redeemable Convertible Preferred Stock 07 Feb 2024 Common Stock 1,940,388 See Footnote F1, F2
holding KYTX Series B Redeemable Convertible Preferred Stock 07 Feb 2024 Common Stock 880,364 See Footnote F1, F2
holding KYTX Series B Redeemable Convertible Preferred Stock 07 Feb 2024 Common Stock 735,984 See Footnote F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock has no expiration date and is convertible into the Issuer's Common Stock on a 1-for-4.5511 basis at any time. The number of underlying shares of Common Stock reported in Column 3 reflects an automatic conversion of each outstanding share of Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock into shares of Common Stock at a ratio of 1-for-4.5511 to be effective immediately prior to the closing of the Issuer's initial public offering.
F2 Shares held directly by Westlake BioPartners Fund I, L.P. ("Westlake I"). The general partner of Westlake I is Westlake BioPartners GP I, LLC ("Westlake GP I"). The voting and dispositive control over Westlake GP I is shared by the managing directors of Westlake GP I, Beth Seidenberg and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any.
F3 Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I"). The voting and dispositive control over Westlake Opportunity GP I is shared by the managing directors of Westlake Opportunity GP I, Beth Seidenberg and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of such person's pecuniary interest therein, if any.

Remarks:

Exhibit 24 - Power of Attorney